Pulse Biosciences names Jon Skinner as CFO

Pulse Biosciences names new CFO, continuing string of C-suite changes
Pulse, which named a new CEO last month, is pitching its pulsed field ablation technology as a way to shorten procedure times.
Pulse Biosciences names Jon Skinner as CFO, effective Feb 3
Pulse Biosciences (PLSE) announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3. “I am excited to announce
Pulse Biosciences has a new CFO
Pulse Biosciences (Nasaq:PLSE) announced today that it appointed Jon Skinner as CFO, effective Feb. 3, 2025.
Pulse Biosciences names Jon Skinner as new CFO
MIAMI - Pulse Biosciences, Inc. (NASDAQ: NASDAQ:PLSE), a bioelectric medicine company focusing on its proprietary CellFX nanosecond Pulsed Field Ablation (nsPFA) technology, has announced the appointment of Jon Skinner as its new Chief Financial Officer,
Pulse Biosciences Appoints Jon Skinner As CFO; Stock Up In Pre-market
Pulse Biosciences, Inc. (PLSE), a novel bioelectric medicine company, Tuesday announced the appointment of Jon Skinner as Chief
Pulse Biosciences Appoints Jon Skinner as Chief Financial Officer
Pulse Biosciences, Inc. (NASDAQ: PLSE) announced the appointment of Jon Skinner as the company’s Chief Financial Officer (CFO), effective February 3, 2025. Alongside his role as CFO, Mr. Skinner will serve as the principal financial officer of the company.
Pulse Biosciences Names Jon Skinner Chief Financial Officer
Pulse Biosciences has hired Jon Skinner as the bioelectric medicine company's new chief financial officer. Pulse on Tuesday said Skinner most recently served as vice president of financial planning and analysis and investor relations at private-equity backed industrial company Copeland.
American Association of Individual Investors1d
Why Pulse Biosciences, Inc.’s (PLSE) Stock Is Down 11.28%
Pulse Biosciences, Inc.’s PLSE share price has dipped by 11.28%, which has investors questioning if this is right time to buy ...
Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, ...
Pulse Biosciences reports successful AF treatment in study
MIAMI - Pulse Biosciences, Inc. (NASDAQ:PLSE), a biotech company with a market capitalization of $1.08 billion and an impressive 112% stock return over the past year, has announced promising results ...
Business Wire16d
Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the late ...